PROGRAM Standard Operating Procedure – Laboratory Services			
Title: MIC31000 – MRSA Screen	Policy Number: 15-207-V1		
Program Name: Laboratory Services			
Applicable Domain: Lab, DI and Pharmacy Services			
Additional Domain(s): NA			
Effective Date: 06/05/2025	Next Review Date: 06/05/2028		
Issuing Authority: Director, Laboratory and Diagnostic Imaging Services	Date Approved: 06/05/2025		
Accreditation Canada Applicable Standard: NA			

# **Uncontrolled When Printed**

# **GUIDING PRINCIPLE:**

Specimens are submitted to identify carriers of methicillin-resistant *Staphylococcus aureus* (MRSA). Swabs may be submitted from any body site, but most common are nasal, groin and wound swabs. Combined nasal/axilla/rectal/perineum swabs may also be processed.

## **PURPOSE/RATIONALE:**

This standard operating procedure describes the screening for Methicillin Resistant *Staphylococcus aureus* (MRSA) on admission and as part of Multi-Resistant Organism (MRO) screens.

### **SCOPE/APPLICABILITY:**

This standard operating procedure applies to Medical Laboratory Technologists (MLTs) processing specimens for MRSA screen.

Туре	Swab	
Source	<ul><li>Amie's with or without charcoal</li><li>Bilateral nasal or groin swab</li></ul>	
Source	MRO screen: any site	
Stability	<ul> <li>If the sample is received in the laboratory and processed greater than 48 hours from collection:</li> <li>Add specimen quality comment: "Delayed transport may adversely affect pathogen recovery"</li> </ul>	
Storage Requirements	Room temperature	

### SAMPLE INFORMATION:

criteria for	<ol> <li>Unlabeled/mislabeled swabs</li> <li>Specimen container label does not match patient identification on requisition</li> <li>Duplicate specimens obtained with same collection method from same collection location within 24 hours</li> </ol>
	method from same collection location within 24 hours

### **REAGENTS and/or MEDIA:**

- MRSA*Select* II agar (MRS) and Blood agar (BA)
- Identification reagents: catalase, Staph latex test and tube coagulase

#### SUPPLIES:

- Disposable inoculation needles
- Wooden sticks

#### **EQUIPMENT:**

- Biosafety cabinet
- 35° ambient air incubator
- VITEK 2 and supplies

### **SPECIAL SAFETY PRECAUTIONS:**

Containment Level 2 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials or cultures:

- Ensure that appropriate hand hygiene practices be used
- Lab gown must be worn when performing activities with potential pathogens
- Gloves must be worn when direct skin contact with infected materials is unavoidable
- Eye protection must be used when there is a known or potential risk of exposure of splashes
- All procedures that may produce aerosols, or involve high concentrations or large volumes should be conducted in a biological safety cabinet (BSC)
- The use of needles, syringes and other sharp objects should be strictly limited

All patient specimens are assumed to be potentially infectious. Routine Practices must be followed. Since viable micro-organisms are used, all cultures must be handled with appropriate precautions. All equipment in contact with cultures should be decontaminated by appropriate methods.

## **QUALITY CONTROL:**

- Refer to MIC60040-Culture Media Quality Control procedure
- Refer to Test Manual for reagent quality control procedures

#### **PROCEDURE INSTRUCTIONS:**

Step	Action		
Processing swabs for MRSA screen			
1	<ul> <li>In the biosafety cabinet:</li> <li>Inoculate MRSASelect II agar with the swab</li> <li>Ensure all surfaces of the swab make contact with the agar</li> <li>Streak for isolated growth using a disposable inoculation needle</li> </ul>		
2	Label the MRS plate with: R (Date + 1 day).		
3	<ul> <li>Incubate the media:</li> <li>Place MRS in the O<sub>2</sub> incubator on the "NEW URINE" shelf</li> </ul>		

### **INTERPRETATION OF RESULTS:**

Step	Action		
1	<ul> <li>Observe MRS plate at 18 to 24 hours (9:00 to 15:00)</li> <li>Examine for pink colonies</li> </ul>		
2	<ul> <li>If no pink colonies are seen at 18 to 24 hours:</li> <li>Record observations in the LIS</li> <li>Workup complete, MRSA not isolated</li> </ul>		
3	<ul> <li>If pink colonies are seen:</li> <li>Record observations in the LIS</li> <li>If isolated colonies are present, perform Staph latex test</li> <li>If no isolated colonies are present, subculture pink colonies to BA</li> </ul>		
	IF	THEN	
4	Staph latex test NEGATIVE	<ul> <li>Record observations in the LIS</li> <li>Workup complete</li> <li>MRSA not isolated</li> </ul>	
	Staph latex test POSITIVE	<ul> <li>Record observations in the LIS</li> <li>Select key 4 to add the media TC and Panel and to add the organism <i>Staphylococcus aureus</i></li> <li>Perform TC</li> <li>Perform GPS</li> </ul>	

#### NOTE:

- If both nares and groin swabs have pink colonies, only 1 needs to be worked up
- If isolate that is worked up as per procedure is MRSA, non-worked up sample can be identified as *Staphylococccus aureus* and MRSA comment &cx00 can be added

### **REPORTING INSTRUCTIONS:**

IF	REPORT	
No pink colonies	<ul> <li>Report: "No Methicillin Resistant Staph aureus (MRSA) isolated"</li> </ul>	
Pink colonies, Staph latex test NEGATIVE	<ul> <li>Report: "No Methicillin Resistant Staph aureus (MRSA) isolated"</li> </ul>	
Staph latex test POSITIVE Tube coagulase test NEGATIVE GPS Cefoxitin Screen POSITIVE or NEGATIVE	<ul> <li>Record observations in the LIS</li> <li>Verify Panel results:         <ul> <li>Keep GPS results suppressed</li> </ul> </li> <li>Suppress Staphylococcus aureus isolate ID:         <ul> <li>Change isolate # to a letter</li> </ul> </li> <li>Report: "No Methicillin Resistant Staph aureus (MRSA) isolated"</li> </ul>	
Staph latex test POSITIVE Tube coagulase test POSITIVE GPS Cefoxitin Screen NEGATIVE	<ul> <li>Record observations in the LIS</li> <li>Verify Panel results:         <ul> <li>Keep GPS results suppressed</li> </ul> </li> <li>Suppress Staphylococcus aureus isolate ID:             <ul> <li>Change isolate # to a letter</li> </ul> </li> <li>Report: "No Methicillin Resistant Staph aureus (MRSA) isolated"</li> </ul>	
Staph latex test POSITIVE Tube coagulase test POSITIVE GPS Cefoxitin Screen POSITIVE	<ul> <li>Record observations in the LIS</li> <li>Verify Panel results:</li> <li>Keep GPS results suppressed</li> <li>Verify the organism ID <i>Staphylococcus aureus</i></li> <li>Ensure the quantitation is entered as "Isolated"</li> <li>The following isolate comment will be added: &amp;cx00</li> <li>In order entry, copy report to OCPHO (HPU1)</li> <li>In order entry, check the home address of the patient. If from Nunavut, copy report to the applicable NU CPHO</li> <li>In order entry, copy report to appropriate IPAC</li> <li>In order entry, add ESO code "MRSA"</li> </ul>	

**NOTE:** STH IPAC ward is **SIPAC**. IRH IPAC ward is **IIPAC** 

## LIMITATIONS:

- 1. Prolonged exposure to light (>8h) may result in reduced recovery and/or colouration of the QC organisms or patient isolates. Minimize exposure of plates to light both before and during incubation.
- 2. Incubation in CO<sub>2</sub> may result in false negative cultures. Incubate only in ambient air incubator.
- 3. Performance of this agar has been optimized for incubation at 35°C to 37°C for 18 to 28 hours. Plates can be read any time within this timeframe. Lower or higher incubation temperatures and/or incubation times <18 hours may reduce the sensitivity of the agar.

4. Some strains of *Corynebacterium imitans*, *Aerocuccus viridans* and *Staphylococcus cohnii* may develop heterogeneous pinkish colonies with a more intense colouration when in clusters, but colourless when colonies are isolated (which enables differentiation from MRSA colonies).

# **CROSS-REFERENCES:**

• MIC60040-Culture Media Quality Control

# **REFERENCES:**

- 1. Leber, A. (2016). *Clinical microbiology procedures handbook.* (4<sup>th</sup>ed.) Washington, D.C.: ASM Press
- Jorgensen J.H., Pfaller M.A., Carroll K.C., Funke G., Landry M.L., Richter S.S., Warnock D.W. (2015). *Manual of Clinical Microbiology*, 11<sup>th</sup> edition. Washington, D.C: ASM Press
- 3. Bio-Rad. (2016/03). MRSASelect II package insert

# **APPROVAL:**

May 06, 2025

Date Ph

Acting Director, Laboratory and Diagnostic Imaging Services

# **REVISION HISTORY:**

REVISION	DATE	Description of Change	REQUESTED BY
1.0	11 Jan 17	Initial Release	L. Steven
2.0	30 Nov 18	Updated to include new VITEK 2 instrument	L. Steven
3.0	30 Dec 21	Procedure reviewed and added to NTHSSA policy template	L. Steven
4.0	31 Aug 22	Updated to reflect new MRSA agar MRSA <i>Select</i> II	L. Steven
4.1	19 Mar 25	Periodic Review; Updated date format in revision history table	L. Steven